Evolus Stock Price, News & Analysis

Evolus (NASDAQ: EOLS), a performance beauty company, has appointed Tatjana Mitchell as its new Chief Financial Officer, effective September 8, 2025. Mitchell brings over 20 years of strategic and operational finance leadership experience, most recently serving as Senior Vice President of Corporate Finance at Experian, where she managed financial planning across six business units representing $5+ billion in revenue.

At Experian, Mitchell demonstrated success in driving double-digit organic revenue growth, executing acquisitions, and improving EBITDA margins. Her previous roles include CFO positions at Zulily, and finance leadership positions at Forever 21, Macy's, Gap Inc., and Marriott International. Mitchell holds an MBA from The Wharton School and a BS in Business Administration from Towson University.

Evolus (NASDAQ: EOLS) announced positive topline results from its U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid gel product for mid-face volume restoration. The study demonstrated statistical superiority over Restylane®-Lyft, with Evolysse™ Sculpt achieving a 90.9% responder rate compared to 83.3% for Restylane®-Lyft.

The company has submitted a Premarket Approval (PMA) application to the FDA, with approval expected in the second half of 2026. The product, manufactured using innovative Cold-X™ technology, showed a favorable safety profile with no treatment-related serious adverse events. This development marks a significant expansion beyond Evolus' existing Jeuveau® product line.

Evolus (NASDAQ: EOLS) has submitted its final Premarket Approval (PMA) application to the FDA for Evolysse™ Sculpt, an injectable hyaluronic acid gel designed for mid-face volume restoration. The submission follows completion of a pivotal clinical trial involving 304 patients comparing Evolysse™ Sculpt to Restylane®-Lyft in a double-blinded, controlled study.

The product, manufactured using innovative Cold-X™ technology, is positioned to enter the high-value mid-face dermal filler segment. FDA approval is anticipated in the second half of 2026. Evolysse™ Sculpt is expected to be the flagship product in the company's Evolysse™ collection, featuring technology that preserves the natural structure of HA molecules for long-lasting results.

Evolus (NASDAQ: EOLS), a performance beauty company, has announced the grant of 12,731 restricted stock units (RSUs) to 5 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The grants were approved by the company's compensation committee with a grant date of August 7, 2025.

The RSUs will vest over a four-year period, with 25% vesting on each annual anniversary of the vesting commencement date. Continued employment is required for vesting, and the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus (NASDAQ: EOLS) reported Q2 2025 financial results with global net revenue of $69.4 million, up 4% year-over-year despite market headwinds. The growth was driven by the successful launch of Evolysse™, which contributed $9.7 million in revenue, and strong international performance.

The company reported a GAAP operating loss of $10.2 million and ended the quarter with $61.7 million in cash. Evolus revised its 2025 revenue guidance to $295-305 million and expects to achieve profitability in Q4 2025. The company maintains its 2028 revenue target of $700 million with projected non-GAAP operating margins of 20%.

Key operational metrics include over 16,500 total purchasing accounts, a 70% reorder rate, and 1.2 million members in the Evolus Rewards™ program. The company announced cost optimization measures expected to yield $25 million in non-GAAP operating expense savings for 2025.

Evolus (NASDAQ: EOLS) announced the publication of a landmark independent study in JAMA Dermatology comparing four FDA-approved neurotoxins for treating glabellar lines. The double-blind study of 143 female participants aged 30-65 demonstrated Jeuveau®'s superior performance against competitors Botox®, Dysport®, and Xeomin®.

Key findings showed that Jeuveau® achieved the highest peak effect with a 93% median strain reduction at Day 30, demonstrated fast onset of action at Day 3, and maintained significant duration at Day 180, outperforming Botox® at this timepoint. The study validates Jeuveau®'s market success, which has achieved over 14% U.S. market share and penetrated more than 50% of aesthetic clinics, becoming the fastest-growing neurotoxin for four consecutive years.

Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetic consumer brands, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close.

Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the webcast on Evolus's Investor Relations webpage.

Evolus (NASDAQ: EOLS), a performance beauty company, has granted 12,385 restricted stock units (RSUs) to 6 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The RSUs were granted on July 7, 2025, as approved by the company's compensation committee.

The RSUs will vest over a four-year period, with 25% vesting annually on each anniversary of the grant date. Continuous employment is required for vesting, and the awards are subject to the terms and conditions of both the Incentive Plan and respective RSU agreements.

Evolus (NASDAQ: EOLS) has announced its expansion into the French market through a partnership with Symatese for the distribution of Nuceiva® (botulinum toxin type A). The product is approved by the European Commission for treating moderate to severe glabellar lines in adults under 65 years.

Nuceiva®, marketed as Jeuveau® in the United States, has been the fastest-growing neurotoxin in the U.S. for four consecutive years. The product's safety and efficacy were validated through the TRANSPARENCY clinical program, which included three Phase III trials and two long-term safety studies, featuring the largest head-to-head aesthetic pivotal study versus Botox® to date.

The partnership with Symatese, a French company specializing in regenerative medical solutions, will enable direct order and delivery to French medical aesthetics healthcare professionals.